XORTX Therapeutics Inc.

corporate_fare Company Profile

XORTX Therapeutics Inc.

XRTX·NASDAQ·Life Sciences·CIK 0001729214

XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing and commercializing treatments for diseases linked to high uric acid levels in Canada. The company is developing several therapies: XRx-026, which is in Phase III clinical trials for treating gout; XRx-008, currently in Phase II for autosomal dominant polycystic kidney disease; and XRx-101, also in Phase II, for acute kidney injury resulting from respiratory virus infections, including sepsis and coronavirus. Additionally, XRX-225 is in the preclinical stage for treating type 2 diabetic nephropathy. XORTX Therapeutics Inc. also has a program called VB4-P5, which aims to treat and prevent kidney fibrosis. The company operates from Calgary, Canada.

XORTX Therapeutics Inc. (NASDAQ:XRTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for XRTX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

XORTX Proposes Reverse Stock Split to Avoid Delisting Amid Going Concern Doubts and Pending Highly Dilutive Acquisition (2026-03-03)
XORTX Therapeutics Faces Going Concern Doubt and Nasdaq Delisting Risk Amid Significant Cash Burn (2026-02-27)
XORTX Therapeutics Files for Highly Dilutive $5M Offering of Shares and Warrants at a Discount (2026-02-12)
XORTX Therapeutics Extends Deadline for Renal Anti-Fibrotic Program Acquisition (2026-02-04)
XORTX Therapeutics Announces Pioneering Research Validating Gout & Kidney Disease Therapeutic Strategy (2026-01-02)

Financial Snapshot

Fiscal year ended December 31, 2025

Net Income

-$2.66M

Diluted EPS

-$0.56

Op. Cash Flow

-$2.77M

Cash & Equivalents

$864.51K

Debt / Equity

0.00×

Shares Outstanding

6.96M sh

Source: 20-F · filed 2026-03-20 · accession 0001104659-26-032775

Insider Transactions

XRTX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

show_chartPrice Chart

Loading chart...

feed XRTX - Filings & News (Page 2)

Filing Type

Date Range

XRTX

Mar 03, 2026, 10:08 AM EST

Filing Type: 6-K

Importance Score:

XORTX Proposes Reverse Stock Split to Avoid Delisting Amid Going Concern Doubts and Pending Highly Dilutive Acquisition

Price at Filing: $0.400

Real-time Price: $1.73

Change: Reverse Stock Split

Market Cap: $3.114M

Sentiment: Negative

View Wiseek Article

XRTX

Feb 27, 2026, 7:39 AM EST

Filing Type: 6-K

Importance Score:

XORTX Therapeutics Faces Going Concern Doubt and Nasdaq Delisting Risk Amid Significant Cash Burn

Price at Filing: $0.380

Real-time Price: $1.73

Change: Reverse Stock Split

Market Cap: $3.114M

Sentiment: Negative

View Wiseek Article

XRTX

Feb 12, 2026, 6:34 PM EST

Filing Type: F-1/A

Importance Score:

XORTX Therapeutics Files for Highly Dilutive $5M Offering of Shares and Warrants at a Discount

Price at Filing: $0.4372

Real-time Price: $1.73

Change: Reverse Stock Split

Market Cap: $3.114M

Sentiment: Negative

View Wiseek Article

XRTX

Feb 04, 2026, 6:00 PM EST

Filing Type: 6-K

Importance Score:

XORTX Therapeutics Extends Deadline for Renal Anti-Fibrotic Program Acquisition

Price at Filing: $0.5458

Real-time Price: $1.73

Change: Reverse Stock Split

Market Cap: $3.114M

Sentiment: Neutral

View Wiseek Article

XRTX

Jan 02, 2026, 2:38 PM EST

Filing Type: 6-K

Importance Score:

XORTX Therapeutics Announces Pioneering Research Validating Gout & Kidney Disease Therapeutic Strategy

Price at Filing: $0.590

Real-time Price: $1.73

Change: Reverse Stock Split

Market Cap: $3.114M

Sentiment: Positive

View Wiseek Article

Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets

corporate_fare Company Profile